{"id":"NCT00735397","sponsor":"Eisai Inc.","briefTitle":"Evaluation of the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures","officialTitle":"An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Studies to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-10","primaryCompletion":"2014-09","completion":"2014-09","firstPosted":"2008-08-14","resultsPosted":"2016-01-26","lastUpdate":"2016-03-14"},"enrollment":1218,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy"],"interventions":[{"type":"DRUG","name":"perampanel","otherNames":[]}],"arms":[{"label":"Perampanel","type":"EXPERIMENTAL"}],"summary":"The purpose of this study was to evaluate the safety and tolerability of perampanel (up to 12 mg/day) given as adjunctive treatment in subjects with refractory partial seizures and to evaluate the maintenance of effect of perampanel for the control of refractory partial seizures.","primaryOutcome":{"measure":"Number of Participants With Treatment-emergent Non-Serious Adverse Events (AEs) and Treatment-emergent Serious Adverse Events (SAEs)","timeFrame":"From date of first dose of perampanel up to 30 days after the last dose of perampanel or up to approximately 5 years.","effectByArm":[{"arm":"Perampanel","deltaMin":1018,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":239,"countries":["United States","Argentina","Australia","Austria","Belgium","Bulgaria","Canada","Chile","China","Czechia","Estonia","Finland","France","Germany","Greece","Hong Kong","Hungary","India","Israel","Italy","Latvia","Lithuania","Malaysia","Mexico","Netherlands","Philippines","Poland","Portugal","Romania","Russia","Serbia","South Africa","South Korea","Spain","Sweden","Taiwan","Thailand","Ukraine","United Kingdom"]},"refs":{"pmids":["35305920","29574701","25823975","24867391"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":288,"n":1216},"commonTop":["Dizziness","Somnolence","Headache","Fatigue","Weight increased"]}}